Amneal Pharmaceuticals, Inc. - Class A Common Stock (AMRX)
12.24
+0.24 (1.96%)
NASDAQ · Last Trade: Dec 3rd, 1:53 PM EST
Detailed Quote
Previous Close
12.00
Open
12.12
Bid
12.23
Ask
12.24
Day's Range
12.03 - 12.30
52 Week Range
6.685 - 12.68
Volume
577,133
Market Cap
12.24K
PE Ratio (TTM)
611.75
EPS (TTM)
0.0
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,889,065
Chart
About Amneal Pharmaceuticals, Inc. - Class A Common Stock (AMRX)
Amneal Pharmaceuticals is a leading pharmaceutical company focused on the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The company offers a broad portfolio of high-quality, cost-effective medications across various therapeutic areas, including central nervous system disorders, infectious diseases, and pain management. Amneal is committed to improving access to essential medications through innovation in drug formulation and delivery. With a robust pipeline of products and a dedication to regulatory compliance, Amneal aims to meet the diverse needs of patients and healthcare providers while contributing to the overall efficiency of the healthcare system. Read More
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately -
over the past six months, healthcare stocks have gained 15.5%, nearly mirrorring the S&P 500.
BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financial Officer, will participate in following upcoming investor conferences:
BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company’s cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. The product is the generic equivalent of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, a registered trademark of Allergan, an AbbVie company.
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
Looking back on generic pharmaceuticals stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Amneal (NASDAQ:AMRX) and its peers.
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names.
But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks.
But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices.
But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX)
jumped 8.9% in the afternoon session after the company reported strong third-quarter financial results that surpassed expectations and raised its full-year forecast.
Amneal Pharmaceuticals Q3 2025 earnings beat profit estimates, driving a stock surge. The company also raised its full-year guidance for EBITDA and EPS.
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 11.7% year on year to $784.5 million. The company’s full-year revenue guidance of $3.05 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $0.17 per share was 22.9% above analysts’ consensus estimates.
‒ Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒‒ Adjusted EBITDA of $160 million; Adjusted Diluted EPS of $0.17 ‒‒ Updated 2025 Full Year Guidance ‒
BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the U.S. commercial launch of Brekiya® (dihydroergotamine mesylate) injection, the first and only ready-to-use dihydroergotamine (DHE) autoinjector approved for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.1,2 The Brekiya autoinjector is now available by prescription exclusively through Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
